Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 5
Submit an article Journal homepage
4,663
Views
126
CrossRef citations to date
0
Altmetric
Original Research

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

A. AsgarovaUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
K. AsgarovUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
Y. GodetUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France;University Hospital of Besançon, Medical Oncology Department, Besançon, FranceView further author information
,
P. PeixotoUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France;EPIGENExp (EPIgenetics and GENe EXPression Technical Platform), Besançon, FranceView further author information
,
A. NadaradjaneINSERM unit S1232, University of Nantes, Nantes, France;Institut de cancérologie de l'Ouest, Nantes, France;member of the REpiCGO (Cancéropole Grand-Ouest, France) and EpiSAVMEN (Région Pays de la Loire, France) networks, FranceView further author information
,
M. Boyer-GuittautUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
J. GalaineUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
D. GuenatUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
V. MougeyUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
J. PerrardUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
J. R. PallandreUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
A. BouardUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
J. BallandUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
C. TiroleUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
O. AdoteviUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France;University Hospital of Besançon, Medical Oncology Department, Besançon, FranceView further author information
,
E. HendrickUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, FranceView further author information
,
M. HerfsLaboratory of Experimental Pathology, GIGA-Cancer, University of Liege, Liege, BelgiumView further author information
,
P. F. CartronINSERM unit S1232, University of Nantes, Nantes, France;Institut de cancérologie de l'Ouest, Nantes, France;member of the REpiCGO (Cancéropole Grand-Ouest, France) and EpiSAVMEN (Région Pays de la Loire, France) networks, FranceView further author information
,
C. BorgUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France;University Hospital of Besançon, Medical Oncology Department, Besançon, France;Clinical Investigation center-Biotherapy 1431, Besançon, FranceCorrespondence[email protected]
View further author information
&
E. HervouetUniv. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France;EPIGENExp (EPIgenetics and GENe EXPression Technical Platform), Besançon, FranceCorrespondence[email protected]
View further author information
 show all
Article: e1423170 | Received 28 Sep 2017, Accepted 22 Dec 2017, Published online: 01 Feb 2018

Citations (126)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Honghong Fan, Yuxin Shi, Huiyu Wang, Yuting Li, Jie Mei, Junying Xu & Chaoying Liu. (2023) GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC. International Journal of General Medicine 16, pages 1757-1769.
Read now
Dan Xu, Jing Li, Rui-Yang Li, Ting Lan, Chi Xiao & Ping Gong. (2019) PD-L1 Expression Is Regulated By NF-κB During EMT Signaling In Gastric Carcinoma. OncoTargets and Therapy 12, pages 10099-10105.
Read now
Cong Bo, Qiang Wu, Hai Zhao, Xuebing Li & Qinghua Zhou. (2018) Thymosin α1 suppresses migration and invasion of PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3–MMP2 signaling. OncoTargets and Therapy 11, pages 7255-7270.
Read now
Cao Bin, He Xiaofeng & Xu Wanzi. (2018) The effect of microRNA-129 on the migration and invasion in NSCLC cells and its mechanism. Experimental Lung Research 44:6, pages 280-287.
Read now

Articles from other publishers (122)

Sridhar Kandala, Maria Ramos, Lena Voith von Voithenberg, Alberto Diaz-Jimenez, Sara Chocarro, Johanna Keding, Benedikt Brors, Charles D. Imbusch & Rocio Sotillo. (2023) Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer. Cell Reports 42:12, pages 113266.
Crossref
Jinghan Yang, Liang Qiu, Xi Wang, Xi Chen, Pingdong Cao, Zhe Yang & Qiang Wen. (2023) Liquid biopsy biomarkers to guide immunotherapy in breast cancer. Frontiers in Immunology 14.
Crossref
Alesha A Thai, Richard J Young, Mathias Bressel, Christopher Angel, Lachlan McDowell, Albert Tiong, Nicholas W Bucknell, Andrew Fellowes, Huiling Xu, Anna Trigos, Danny Rischin & Benjamin J Solomon. (2023) Comprehensive profiling identifies tumour and immune microenvironmental differences in clinical subsets of cutaneous squamous cell carcinoma. British Journal of Dermatology 189:5, pages 588-602.
Crossref
Caecilia Sukowati, Loraine Kay D. Cabral, Beatrice Anfuso, Francesco Dituri, Roberto Negro, Gianluigi Giannelli & Claudio Tiribelli. (2023) PD-L1 Downregulation and DNA Methylation Inhibition for Molecular Therapy against Cancer Stem Cells in Hepatocellular Carcinoma. International Journal of Molecular Sciences 24:17, pages 13357.
Crossref
Thomas J. Gerton, Allen Green, Marco Campisi, Minyue Chen, Iliana Gjeci, Navin Mahadevan, Catherine A. A. Lee, Ranjan Mishra, Ha V. Vo, Koji Haratani, Ze-Hua Li, Kathleen T. Hasselblatt, Bryanna Testino, Trevor Connor, Christine G. Lian, Kevin M. Elias, Patrick Lizotte, Elena V. Ivanova, David A. Barbie & Daniela M. Dinulescu. (2023) Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells. Cancers 15:16, pages 4128.
Crossref
Eyoel Yemanaberhan Lemma, Anudari Letian, Nasser K. Altorki & Timothy E. McGraw. (2023) Regulation of PD-L1 Trafficking from Synthesis to Degradation. Cancer Immunology Research 11:7, pages 866-874.
Crossref
Yu-Ping Chang, Gong-Kai Huang, Yung-Che Chen, Kuo-Tung Huang, Yu-Mu Chen, Chiung-Yu Lin, Chao-Cheng Huang, Meng-Chih Lin & Chin-Chou Wang. (2023) E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis. BMC Cancer 23:1.
Crossref
Jintao Wu, Xinyu Yu, Hongyu Zhu, Peng Chen, Tongyan Liu, Rong Yin, Yan Qiang & Lin Xu. (2023) RelB is a potential molecular biomarker for immunotherapy in human pan-cancer. Frontiers in Molecular Biosciences 10.
Crossref
Antoinette van Weverwijk & Karin E. de Visser. (2023) Mechanisms driving the immunoregulatory function of cancer cells. Nature Reviews Cancer 23:4, pages 193-215.
Crossref
Trine V. Larsen, Nina Dybdal, Tina F. Daugaard, Johanne Lade-Keller, Lin Lin, Boe S. Sorensen & Anders L. Nielsen. (2023) Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer. Cancers 15:6, pages 1909.
Crossref
Yiwei Xu, Xiaodong Hao, Yidan Ren, Qinchen Xu, Xiaoyan Liu, Shuliang Song & Yunshan Wang. (2023) Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. Frontiers in Oncology 12.
Crossref
晓梅 苏. (2023) Research Progress of PD-L1 in Non-Small Cell Lung Cancer. Advances in Clinical Medicine 13:10, pages 16462-16467.
Crossref
Yaqi Gao, Tianhui Zou, Pingping Xu, Yingchao Wang, Yi Jiang, Ying-Xuan Chen, Haoyan Chen, Jie Hong & Jing-Yuan Fang. (2023) Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer. Neoplasia 35, pages 100850.
Crossref
Lu Liu, Yuxi Lei, Wensheng Chen, Qian Zhou, Zongyao Zheng, Guandi Zeng, Wanting Liu, Pengju Feng, Zhiyi Zhang, Lei Yu & Liang Chen. (2022) In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF-κB modulator in lung cancer. Cell & Bioscience 12:1.
Crossref
Gerhard A. Burger, Daphne N. Nesenberend, Carlijn M. Lems, Sander C. Hille & Joost B. Beltman. (2022) Bidirectional crosstalk between epithelial–mesenchymal plasticity and IFN γ -induced PD-L1 expression promotes tumour progression . Royal Society Open Science 9:11.
Crossref
Kyung-Soo Chun, Do-Hee Kim, Pawan Kumar Raut & Young-Joon Surh. (2022) Anticancer natural products targeting immune checkpoint protein network. Seminars in Cancer Biology 86, pages 1008-1032.
Crossref
Srinath Muralidharan, Manas Sehgal, R. Soundharya, Susmita Mandal, Sauma Suvra Majumdar, M. Yeshwanth, Aryamaan Saha & Mohit Kumar Jolly. (2022) PD-L1 Activity Is Associated with Partial EMT and Metabolic Reprogramming in Carcinomas. Current Oncology 29:11, pages 8285-8301.
Crossref
Junwei Kang, Zhiying Zheng, Xian Li, Tian Huang, Dawei Rong, Xinyang Liu, Miaomiao Qin, Yuliang Wang, Xiangyi Kong, Jinhua Song, Chengyu Lv & Xiongxiong Pan. (2022) Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma. Cancer Cell International 22:1.
Crossref
Monika Devanaboyina, Jasskiran Kaur, Emma Whiteley, Leslie Lin, Katelyn Einloth, Susan Morand, Laura Stanbery, Danae Hamouda & John Nemunaitis. (2022) NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer. Oncology Reviews 16.
Crossref
Xiaoran Ma, Jibiao Wu, Bin Wang, Cun Liu, Lijuan Liu & Changgang Sun. (2022) Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review). International Journal of Oncology 61:5.
Crossref
Yunxia Ma, Rumyana Marinkova, Miljana Nenkov, Lai Jin, Otmar Huber, Jürgen Sonnemann, Natália Peca, Nikolaus Gaßler & Yuan Chen. (2022) Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt/β-Catenin Pathway in Human Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 23:19, pages 11031.
Crossref
Francesca Pirini, Daniele Vergara & Paola Parrella. (2022) Editorial: Tumor microenvironment signaling networks in pathophysiology and therapeutics. Frontiers in Oncology 12.
Crossref
Emily L. LaPlante, Dongliang Liu, Varduhi Petrosyan, Qizhi Yao & Aleksandar Milosavljevic. (2022) XDec-CHI reveals immunosuppressive interactions in pancreatic ductal adenocarcinoma. iScience, pages 105249.
Crossref
Jiahui Lu, Fei Fei, Chenxi Wu, Jie Mei, Junying Xu & Peihua Lu. (2022) ZEB1: Catalyst of immune escape during tumor metastasis. Biomedicine & Pharmacotherapy 153, pages 113490.
Crossref
Eslam E. Abd El-Fattah & Amr Y. Zakaria. (2022) Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach. International Immunopharmacology 109, pages 108889.
Crossref
Qinying Sun, Xiangzhen Wei, Zhonglin Wang, Yan Zhu, Weiying Zhao & Yuchao Dong. (2022) Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer. Cancers 14:14, pages 3294.
Crossref
Zhe Li, Xiao-Jing Ding, Xin Qiao, Xiao-Meng Liu, Xin Qiao, Cheng-Zhi Xie, Rui-Ping Liu & Jing-Yuan Xu. (2022) Thalidomide-based Pt(IV) prodrugs designed to exert synergistic effect of immunomodulation and chemotherapy. Journal of Inorganic Biochemistry 232, pages 111842.
Crossref
Sepideh Mirzaei, Sam Saghari, Farzaneh Bassiri, Rasoul Raesi, Ali Zarrabi, Kiavash Hushmandi, Gautam Sethi & Vinay Tergaonkar. (2022) NF‐κB as a regulator of cancer metastasis and therapy response: A focus on epithelial–mesenchymal transition. Journal of Cellular Physiology 237:7, pages 2770-2795.
Crossref
Sabine Groeger, Fan Wu, Florian Wagenlehner, Temuujin Dansranjav, Sabine Ruf, Fabian Denter & Joerg Meyle. (2022) PD-L1 Up-Regulation in Prostate Cancer Cells by Porphyromonas gingivalis. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Qinghua Wu, Li You, Eugenie Nepovimova, Zbynek Heger, Wenda Wu, Kamil Kuca & Vojtech Adam. (2022) Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. Journal of Hematology & Oncology 15:1.
Crossref
Yalda Amiri Hezave, Zohreh Sharifi, Fahime Ranjbar Kermani & Majide Shahabi. (2022) Association of the rs4143815 polymorphism of PDL1 gene with HTLV‐1 infection and proviral load in asymptomatic blood donors in northeast Iran. Microbiology and Immunology 66:6, pages 324-329.
Crossref
Malina Xiao, Caroline Duhem, Anwar Chammout, Guy Berchem & Bassam Janji. (2022) CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT. Journal of Cellular Biochemistry 123:6, pages 1025-1031.
Crossref
Irena Wieleba, Kamila Wojas-Krawczyk, Izabela Chmielewska, Magdalena Wójcik-Superczyńska, Paweł Krawczyk & Janusz Milanowski. (2022) In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation. Scientific Reports 12:1.
Crossref
Yanyan Zhang, Shuyi Zhu, Yuanyuan Du, Fan Xu, Wenbo Sun, Zhi Xu, Xiumei Wang, Peipei Qian, Qin Zhang, Jifeng Feng & Yong Xu. (2022) RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Wei Wu, Yichang Wang, Chen Niu, Alafate Wahafu, Longwei Huo, Xiaoye Guo, Jianyang Xiang, Xiaodong Li, Wanfu Xie, Xiaobin Bai, Maode Wang & Jia Wang. (2021) Retinol binding protein 1‐dependent activation of NF‐ κB signaling enhances the malignancy of non‐glioblastomatous diffuse gliomas. Cancer Science 113:2, pages 517-528.
Crossref
Fei-fei Xu, Hui-min Sun, Run-ping Fang, Lu Zhang, Hui Shi, Xue Wang, Xue-li Fu, Xian-meng Li, Xu-he Shi, Yue Wu, Kai Ye, Wei-ying Zhang & Li-hong Ye. (2021) The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth. Acta Pharmacologica Sinica 43:2, pages 429-445.
Crossref
Takwa Bedhiafi, Varghese Philipose Inchakalody, Queenie Fernandes, Sarra Mestiri, Nashiru Billa, Shahab Uddin, Maysaloun Merhi & Said Dermime. (2022) The potential role of vitamin C in empowering cancer immunotherapy. Biomedicine & Pharmacotherapy 146, pages 112553.
Crossref
Cho Mar Myint Wai, Shangying Chen, The Phyu, Shuangyi Fan, Sai Mun Leong, Wenning Zheng, Louis Ching Yi Low, Shoa-Nian Choo, Chi-Kuen Lee, Tae-Hoon Chung, Kenneth Hon Kim Ban, Soumita Ghosh, Stefanus Lie, Seiichi Kato, Shigeo Nakamura, Emiko Takahashi, Young-Hyeh Ko, Joseph D. Khoury, Shih-Sung Chuang, Rex K.H. Au-Yeung, Soo-Yong Tan, Soon-Thye Lim, Choon-Kiat Ong, Yong-Howe Ho, Li Mei Poon, Sanjay De Mel, Anand D. Jeyasekharan, Wee-Joo Chng, Franziska Otto, Leticia Quintanilla-Martinez, Federica Zanardi, Fabio Iannelli, Claudio Tripodo, Jason J. Pitt & Siok-Bian Ng. (2022) Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica 107:8, pages 1864-1879.
Crossref
Yong Zeng, Zhe Zhang, Hongqiang Chen, Jun Fan, Wenbo Yuan, Jingzhi Li, Shimeng Zhou & Wenbin Liu. (2022) Comprehensive Analysis of Immune Implication and Prognostic Value of IFI44L in Non-Small Cell Lung Cancer. Frontiers in Oncology 11.
Crossref
Julien Ancel, Maxime Dewolf, Gaëtan Deslée, Béatrice Nawrocky-Raby, Véronique Dalstein, Christine Gilles & Myriam Polette. (2022) Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions. Cells Tissues Organs 211:2, pages 91-109.
Crossref
Sarthak Sahoo, Sonali Priyadarshini Nayak, Kishore Hari, Prithu Purkait, Susmita Mandal, Akash Kishore, Herbert Levine & Mohit Kumar Jolly. (2021) Immunosuppressive Traits of the Hybrid Epithelial/Mesenchymal Phenotype. Frontiers in Immunology 12.
Crossref
Huanyu Zhang, Guohui Qin, Chaoqi Zhang, Huiyun Yang, Jinyan Liu, Hongwei Hu, Peng Wu, Shasha Liu, Li Yang, Xinfeng Chen, Xueke Zhao, Lidong Wang & Yi Zhang. (2021) TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Yang Sun, Jin Tan, Yuyang Miao & Qiang Zhang. (2021) The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury. Cell Communication and Signaling 19:1.
Crossref
Sara Bravaccini, Giuseppe Bronte, Elisabetta Petracci, Maurizio Puccetti, Manolo D’Arcangelo, Sara Ravaioli, Maria Maddalena Tumedei, Roberta Maltoni, Angelo Delmonte, Federico Cappuzzo & Lucio Crinò. (2021) The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects. Frontiers in Cell and Developmental Biology 9.
Crossref
Sissel Kronborg-White, Line Bille Madsen, Elisabeth Bendstrup & Venerino Poletti. (2021) PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine 10:23, pages 5562.
Crossref
Zhitao Li, Guoqiang Sun, Guangshun Sun, Ye Cheng, Liangliang Wu, Qian Wang, Chengyu Lv, Yichan Zhou, Yongxiang Xia & Weiwei Tang. (2021) Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. Frontiers in Oncology 11.
Crossref
Sareshma Sudhesh Dev, Syafiq Asnawi Zainal Abidin, Reyhaneh Farghadani, Iekhsan Othman & Rakesh Naidu. (2021) Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer. Frontiers in Pharmacology 12.
Crossref
Eslam E. Abd El-Fattah & Amir Mohamed Abdelhamid. (2021) Benzo[a]pyrene immunogenetics and immune archetype reprogramming of lung. Toxicology 463, pages 152994.
Crossref
Balthasar A. Heesters, Kyah van Megesen, Ilhan Tomris, Robert P. de Vries, Giuliana Magri & Hergen Spits. (2021) Characterization of human FDCs reveals regulation of T cells and antigen presentation to B cells. Journal of Experimental Medicine 218:10.
Crossref
N.E. El-Ashmawy, M.L. Salem, E.E. Abd El-Fattah & E.G. Khedr. (2021) Targeting CD166+ lung cancer stem cells: Molecular study using murine dendritic cell vaccine. Toxicology and Applied Pharmacology 429, pages 115699.
Crossref
Samantha M. Morrissey, Fan Zhang, Chuanlin Ding, Diego Elias Montoya-Durango, Xiaoling Hu, Chenghui Yang, Zhen Wang, Fang Yuan, Matthew Fox, Huang-ge Zhang, Haixun Guo, David Tieri, Maiying Kong, Corey T. Watson, Robert A. Mitchell, Xiang Zhang, Kelly M. McMasters, Jian Huang & Jun Yan. (2021) Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metabolism 33:10, pages 2040-2058.e10.
Crossref
Hay-Ran Jang, Sol-Bi Shin, Chang-Hyeon Kim, Jae-Yeon Won, Rong Xu, Da-Eun Kim & Hyungshin Yim. (2021) PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma. Cell Death & Differentiation 28:9, pages 2745-2764.
Crossref
Lei Ding, Hui yu Dong, Tian ren Zhou, Yu hao Wang, Tao Yan, Jun chen Li, Zhong yuan Wang, Jie Li & Chao Liang. (2021) PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. Cancer Medicine 10:18, pages 6384-6401.
Crossref
Rossin Erbe, Zheyu Wang, Sharon Wu, Joanne Xiu, Neeha Zaidi, Jennifer La, David Tuck, Nathanael Fillmore, Nicolas A. Giraldo, Michael Topper, Stephen Baylin, Marc Lippman, Claudine Isaacs, Reva Basho, Ilya Serebriiskii, Heinz-Josef Lenz, Igor Astsaturov, John Marshall, Josephine Taverna, Jerry Lee, Elizabeth M. Jaffee, Evanthia T. Roussos Torres, Ashani Weeraratna, Hariharan Easwaran & Elana J. Fertig. (2021) Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Reports 36:8, pages 109599.
Crossref
Rinku Dutta, Roukiah Khalil, Karthick Mayilsamy, Ryan Green, Mark Howell, Srinivas Bharadwaj, Shyam S. Mohapatra & Subhra Mohapatra. (2021) Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model. Frontiers in Immunology 12.
Crossref
Bin Yi, Hao Cheng, Dorota Wyczechowska, Qingzhao Yu, Li Li, Augusto C. Ochoa, Adam I. Riker & Yaguang Xi. (2021) Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti–PD-L1 Immunotherapy. Molecular Cancer Therapeutics 20:7, pages 1295-1304.
Crossref
Federico Cucchiara, Iacopo Petrini, Chiara Romei, Stefania Crucitta, Maurizio Lucchesi, Simona Valleggi, Cristina Scavone, Annalisa Capuano, Annalisa De Liperi, Antonio Chella, Romano Danesi & Marzia Del Re. (2021) Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. Pharmacological Research 169, pages 105643.
Crossref
Sepideh Mirzaei, Ali Zarrabi, Farid Hashemi, Amirhossein Zabolian, Hossein Saleki, Adnan Ranjbar, Seyed Hesam Seyed Saleh, Morteza Bagherian, Seyed omid Sharifzadeh, Kiavash Hushmandi, Alena Liskova, Peter Kubatka, Pooyan Makvandi, Vinay Tergaonkar, Alan Prem Kumar, Milad Ashrafizadeh & Gautam Sethi. (2021) Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis?. Cancer Letters 509, pages 63-80.
Crossref
Pamela Pinzani, Valeria D’Argenio, Marzia Del Re, Cristina Pellegrini, Federico Cucchiara, Francesca Salvianti & Silvia Galbiati. (2021) Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. Clinical Chemistry and Laboratory Medicine (CCLM) 59:7, pages 1181-1200.
Crossref
Hao Zhang, Ziyu Dai, Wantao Wu, Zeyu Wang, Nan Zhang, Liyang Zhang, Wen-Jing Zeng, Zhixiong Liu & Quan Cheng. (2021) Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Li You, Yingying Zhao, Kamil Kuca, Xu Wang, Patrik Oleksak, Zofia Chrienova, Eugenie Nepovimova, Vesna Jaćević, Qinghua Wu & Wenda Wu. (2021) Hypoxia, oxidative stress, and immune evasion: a trinity of the trichothecenes T-2 toxin and deoxynivalenol (DON). Archives of Toxicology 95:6, pages 1899-1915.
Crossref
Laura Bornes, Guillaume Belthier & Jacco van Rheenen. (2021) Epithelial-to-Mesenchymal Transition in the Light of Plasticity and Hybrid E/M States. Journal of Clinical Medicine 10:11, pages 2403.
Crossref
Camille Lachat, Paul Peixoto & Eric Hervouet. (2021) Epithelial to Mesenchymal Transition History: From Embryonic Development to Cancers. Biomolecules 11:6, pages 782.
Crossref
Giuseppe Bronte, Maurizio Puccetti, Elisabetta Petracci, Lorenza Landi, Paola Cravero, Simona Scodes, Paola Ulivi, Sara Ravaioli, Maria Maddalena Tumedei, Marco Angelo Burgio, Federico Cappuzzo, Angelo Delmonte, Lucio Crinò & Sara Bravaccini. (2021) The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology 11.
Crossref
Shun-Wen Cheng, Po-Chih Chen, Min-Hsuan Lin, Tzong-Rong Ger, Hui-Wen Chiu & Yuan-Feng Lin. (2021) GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer. Biomedicines 9:4, pages 371.
Crossref
Shun-Wen Cheng, Po-Chih Chen, Tzong-Rong Ger, Hui-Wen Chiu & Yuan-Feng Lin. (2021) GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy. Journal of Personalized Medicine 11:3, pages 197.
Crossref
Mariam Markouli, Dimitrios Strepkos, Efthimia K. Basdra, Athanasios G. Papavassiliou & Christina Piperi. (2021) Prominent Role of Histone Modifications in the Regulation of Tumor Metastasis. International Journal of Molecular Sciences 22:5, pages 2778.
Crossref
Yi Sun, Jun Jing, Huan Xu, Lingfan Xu, Hailiang Hu, Cai Tang, Shengzhuo Liu, Qiang Wei, Ruiqi Duan, Ju Guo & Lu Yang. (2021) N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells. Journal for ImmunoTherapy of Cancer 9:3, pages e002138.
Crossref
Luis Del Valle, Lu Dai, Hui‐Yi Lin, Zhen Lin, Jungang Chen, Steven R. Post & Zhiqiang Qin. (2021) Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression. Journal of Cellular and Molecular Medicine 25:6, pages 2795-2805.
Crossref
Soudeh Ghafouri-Fard, Atefe Abak, Zahra Bahroudi, Hamed Shoorei, Sayed Haidar Abbas Raza & Mohammad Taheri. (2021) The interplay between non-coding RNAs and Twist1 signaling contribute to human disorders. Biomedicine & Pharmacotherapy 135, pages 111220.
Crossref
Young Wha Koh, Jae-Ho Han & Seokjin Haam. (2021) Expression of PD-L1, cancer stem cell and epithelial–mesenchymal transition phenotype in non-small cell lung cancer. Pathology 53:2, pages 239-246.
Crossref
Fabrizio Marcucci & Cristiano Rumio. (2020) The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?. Cellular and Molecular Life Sciences 78:3, pages 853-865.
Crossref
Ming Yi, Mengke Niu, Linping Xu, Suxia Luo & Kongming Wu. (2021) Regulation of PD-L1 expression in the tumor microenvironment. Journal of Hematology & Oncology 14:1.
Crossref
Ludovic Peyre, Mickael Meyer, Paul Hofman & Jérémie Roux. (2020) TRAIL receptor-induced features of epithelial-to-mesenchymal transition increase tumour phenotypic heterogeneity: potential cell survival mechanisms. British Journal of Cancer 124:1, pages 91-101.
Crossref
Sridha Ganesh, Rui Wang & Honglei Chen. (2021) Dynamic Monitoring of Immunotherapy Effectiveness with Different Biomarkers in the Patients with Non-Small Cell Lung Cancer. Oncologie 23:3, pages 335-350.
Crossref
Anastasios Gkountakos, Pietro Delfino, Rita T. Lawlor, Aldo Scarpa, Vincenzo Corbo & Emilio Bria. (2021) Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients. Therapeutic Advances in Medical Oncology 13, pages 175883592110069.
Crossref
Mohamed L. Salem, Nahla E. El-Ashmawy, Eslam E. Abd El-Fattah & Eman G. Khedr. (2021) Immunosuppressive role of Benzo[a]pyrene in induction of lung cancer in mice. Chemico-Biological Interactions 333, pages 109330.
Crossref
Laura Boyero, Amparo Sánchez-Gastaldo, Miriam Alonso, José Francisco Noguera-Uclés, Sonia Molina-Pinelo & Reyes Bernabé-Caro. (2020) Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. Cancers 12:12, pages 3729.
Crossref
Yueh-Te Lin & Kou-Juey Wu. (2020) Epigenetic regulation of epithelial-mesenchymal transition: focusing on hypoxia and TGF-β signaling. Journal of Biomedical Science 27:1.
Crossref
Fabrizio Antonangeli, Ambra Natalini, Marina Chiara Garassino, Antonio Sica, Angela Santoni & Francesca Di Rosa. (2020) Regulation of PD-L1 Expression by NF-κB in Cancer. Frontiers in Immunology 11.
Crossref
Hyein Ahn, Hyun Ju Lee, Ji-Hye Lee, Hyun Deuk Cho, Mee-Hye Oh, Ji Woong Son & Si-Hyong Jang. (2020) Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer. Pathology - Research and Practice 216:11, pages 153188.
Crossref
Jiaming He, Wenkan Zhang, Tuoyu Di, Jiahong Meng, Yiying Qi, Guoqi Li, Yuxiang Zhang, Hang Su & Weiqi Yan. (2020) Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody. Biomedicine & Pharmacotherapy 131, pages 110541.
Crossref
Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier-Luigi Lollini, Andrea Ardizzoni & Francesco Gelsomino. (2020) The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. Cancers 12:11, pages 3129.
Crossref
Foteinos-Ioannis D. Dimitrakopoulos, Anastasia E. Kottorou, Melpomeni Kalofonou & Haralabos P. Kalofonos. (2020) The Fire Within: NF-κB Involvement in Non–Small Cell Lung Cancer. Cancer Research 80:19, pages 4025-4036.
Crossref
Nirvana Kalantari Khandani, Atefeh Ghahremanloo & Seyed Isaac Hashemy. (2020) Role of tumor microenvironment in the regulation of PD‐L1: A novel role in resistance to cancer immunotherapy. Journal of Cellular Physiology 235:10, pages 6496-6506.
Crossref
Elena Shklovskaya & Helen Rizos. (2020) Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. International Journal of Molecular Sciences 21:19, pages 7139.
Crossref
Rudi Mao, Xiao Tan, Ying Xiao, Xinyu Wang, Zhixing Wei, Jianing Wang, Xiaoyan Wang, Huaiyu Zhou, Lining Zhang & Yongyu Shi. (2020) Ubiquitin C‐terminal hydrolase L1 promotes expression of programmed cell death‐ligand 1 in non‐small‐cell lung cancer cells. Cancer Science 111:9, pages 3174-3183.
Crossref
Prachya Kongtawelert, Benjawan Wudtiwai, Thuzar Hla Shwe, Peraphan Pothacharoen & Thanyaluck Phitak. (2020) Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin. International Immunopharmacology 86, pages 106759.
Crossref
Shirin Karimi, Sheila Mansouri, Yasin Mamatjan, Jeff Liu, Farshad Nassiri, Suganth Suppiah, Olivia Singh, Kenneth Aldape & Gelareh Zadeh. (2020) Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression. Scientific Reports 10:1.
Crossref
Jia xi Yao, Xiang Chen, Yan jun Zhu, Hang Wang, Xiao yi Hu & Jian ming Guo. (2020) Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma. Frontiers in Oncology 10.
Crossref
Elisabet Cuyàs, Sara Verdura, Begoña Martin-Castillo, Tomás Alarcón, Ruth Lupu, Joaquim Bosch-Barrera & Javier A. Menendez. (2020) Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers 12:7, pages 1757.
Crossref
Anthony Genna, Aline M. Vanwynsberghe, Amélie V. Villard, Charles Pottier, Julien Ancel, Myriam Polette & Christine Gilles. (2020) EMT-Associated Heterogeneity in Circulating Tumor Cells: Sticky Friends on the Road to Metastasis. Cancers 12:6, pages 1632.
Crossref
Annika C. Betzler, Marie-Nicole Theodoraki, Patrick J. Schuler, Johannes Döscher, Simon Laban, Thomas K. Hoffmann & Cornelia Brunner. (2020) NF-κB and Its Role in Checkpoint Control. International Journal of Molecular Sciences 21:11, pages 3949.
Crossref
Milad Ashrafizadeh, Ali Zarrabi, Sedigheh Saberifar, Farid Hashemi, Kiavash Hushmandi, Fardin Hashemi, Ebrahim Rahmani Moghadam, Reza Mohammadinejad, Masoud Najafi & Manoj Garg. (2020) Nobiletin in Cancer Therapy: How This Plant Derived-Natural Compound Targets Various Oncogene and Onco-Suppressor Pathways. Biomedicines 8:5, pages 110.
Crossref
Lianyong Jiang, Xiao Xie, Rui Bi, Fangbao Ding & Ju Mei. (2020) Knockdown of Linc00511 inhibits TGF-β-induced cell migration and invasion by suppressing epithelial-mesenchymal transition and down-regulating MMPs expression. Biomedicine & Pharmacotherapy 125, pages 109049.
Crossref
Zhu Lingling, Liu Jiewei, Wang Li, Yan Danli, Zhou Jie, Li Wen, Pu Dan, Peng Lei & Zhou Qinghua. (2020) Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer. Pathology - Research and Practice 216:4, pages 152852.
Crossref
Alexandros P. Drainas, Ruxandra A. Lambuta, Irina Ivanova, Özdemirhan Serçin, Ioannis Sarropoulos, Mike L. Smith, Theocharis Efthymiopoulos, Benjamin Raeder, Adrian M. Stütz, Sebastian M. Waszak, Balca R. Mardin & Jan O. Korbel. (2020) Genome-wide Screens Implicate Loss of Cullin Ring Ligase 3 in Persistent Proliferation and Genome Instability in TP53-Deficient Cells. Cell Reports 31:1, pages 107465.
Crossref
Dandan Zhang, Liu Yang, Xue Liu, Jiujiao Gao, Tingjiao Liu, Qiu Yan & Xuesong Yang. (2019) Hypoxia modulates stem cell properties and induces EMT through N ‐glycosylation of EpCAM in breast cancer cells . Journal of Cellular Physiology 235:4, pages 3626-3633.
Crossref
Ritu Shrestha, Kim Bridle, Darrell Crawford & Aparna Jayachandran. (2020) TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Molecular Medicine Reports.
Crossref
Kevin Chih-Yang Huang, Shu-Fen Chiang, William Tzu-Liang Chen, Tsung-Wei Chen, Ching-Han Hu, Pei-Chen Yang, Tao-Wei Ke & K. S. Clifford Chao. (2020) Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer. Cancers 12:2, pages 462.
Crossref
F. Böhrnsen, J. Holzenburg, F. Godek, P. Kauffmann, N. Moser & H. Schliephake. (2020) Influence of tumour necrosis factor alpha on epithelial–mesenchymal transition of oral cancer cells in co-culture with mesenchymal stromal cells. International Journal of Oral and Maxillofacial Surgery 49:2, pages 157-165.
Crossref
Mei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang & Do-Youn Oh. (2020) Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. Cancer Research and Treatment 52:1, pages 149-166.
Crossref
Yuanyuan Jiang & Hanxiang Zhan. (2020) Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. Cancer Letters 468, pages 72-81.
Crossref
Dan Lv, Chengjuan Xing, Lin Cao, Yuejian Zhuo, Tao Wu & Na Gao. (2019) PD‑L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer. Oncology Letters.
Crossref
Barbara Seliger. (2019) Basis of PD1/PD-L1 Therapies. Journal of Clinical Medicine 8:12, pages 2168.
Crossref
Gang Xiao, Li-Lian Jin, Chao-Qun Liu, Yong-Chun Wang, Ya-Ming Meng, Zhong-Guo Zhou, Jing Chen, Xing-Juan Yu, Yao-Jun Zhang, Jing Xu & Limin Zheng. (2019) EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Chuanbao Cui, Kaiwen Fu, Lu Yang, Shuzhi Wu, Zuojie Cen, Xingxing Meng, Qiongguang Huang & Zhichun Xie. (2019) Hypoxia-inducible gene 2 promotes the immune escape of hepatocellular carcinoma from nature killer cells through the interleukin-10-STAT3 signaling pathway. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Joséphine Briand, Marie-Pierre Joalland, Arulraj Nadaradjane, Gwenola Bougras-Cartron, Christophe Olivier, François M. Vallette, Sylvain Perruche & Pierre-François Cartron. (2019) Diuron modulates the DNA methylation status of the ILT7 and TRAIL/TNFSF10 genes and decreases the killing activity of plasmacytoid dendritic cells. Environmental Sciences Europe 31:1.
Crossref
Aruna Nambirajan, Prit Benny Malgulwar, Agrima Sharma, Meher Thej Boorgula, Ramesh Doddamani, Manmohan Singh, Vaishali Suri, Chitra Sarkar & Mehar Chand Sharma. (2019) Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?. Brain Tumor Pathology 36:4, pages 152-161.
Crossref
Julien Ancel, Philippe Birembaut, Maxime Dewolf, Anne Durlach, Béatrice Nawrocki-Raby, Véronique Dalstein, Gonzague Delepine, Silvia Blacher, Gaëtan Deslée, Christine Gilles & Myriam Polette. (2019) Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC. Cancers 11:10, pages 1411.
Crossref
P. Hofman, S. Heeke, C. Alix-Panabières & K. Pantel. (2019) Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. Annals of Oncology 30:9, pages 1448-1459.
Crossref
Audrey Lequeux, Muhammad Zaeem Noman, Malina Xiao, Delphine Sauvage, Kris Van Moer, Elodie Viry, Irene Bocci, Meriem Hasmim, Manon Bosseler, Guy Berchem & Bassam Janji. (2019) Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints. Cancer Letters 458, pages 13-20.
Crossref
Yuan Wei, Qiyi Zhao, Zhiliang Gao, Xiang-Ming Lao, Wei-Ming Lin, Dong-Ping Chen, Ming Mu, Chun-Xiang Huang, Zheng-Yu Liu, Bo Li, Limin Zheng & Dong-Ming Kuang. (2019) The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. Journal of Clinical Investigation 129:8, pages 3347-3360.
Crossref
Xiangfeng Shen, Lihong Zhang, Jicheng Li, Yulin Li, Yishu Wang & Zhi-Xiang Xu. (2019) Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Frontiers in Immunology 10.
Crossref
Ruoyang Du, Guanlin Tang, Zhaobing Tang & Youlin Kuang. (2018) Ectopic expression of CC chemokine receptor 7 promotes prostate cancer cells metastasis via Notch1 signaling. Journal of Cellular Biochemistry 120:6, pages 9639-9647.
Crossref
Rama Soundararajan, Jared Fradette, Jessica Konen, Stacy Moulder, Xiang Zhang, Don Gibbons, Navin Varadarajan, Ignacio Wistuba, Debasish Tripathy, Chantale Bernatchez, Lauren Byers, Jeffrey Chang, Alejandro Contreras, Bora Lim, Edwin Parra, Emily Roarty, Jing Wang, Fei Yang, Michelle Barton, Jeffrey Rosen & Sendurai Mani. (2019) Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers 11:5, pages 714.
Crossref
Goran Micevic, Durga Thakral, Meaghan McGeary & Marcus W. Bosenberg. (2018) PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival. Pigment Cell & Melanoma Research 32:3, pages 435-440.
Crossref
Wentao Zhang, Junfeng Zhang, Ziwei Zhang, Yadong Guo, Yuan Wu, Ruiliang Wang, Longsheng Wang, Shiyu Mao & Xudong Yao. (2019) Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer. Translational Oncology 12:3, pages 485-492.
Crossref
Guofu Hu, Nan He, Chuanqi Cai, Fei Cai, Ping Fan, Zhikun Zheng & Xin Jin. (2019) HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer. Pancreatology 19:2, pages 383-389.
Crossref
Paul Peixoto, Amandine Etcheverry, Marc Aubry, Anaïs Missey, Camille Lachat, Jérôme Perrard, Elodie Hendrick, Régis Delage-Mourroux, Jean Mosser, Christophe Borg, Jean-Paul Feugeas, Michaël Herfs, Michaël Boyer-Guittaut & Eric Hervouet. (2019) EMT is associated with an epigenetic signature of ECM remodeling genes. Cell Death & Disease 10:3.
Crossref
Camille Lachat, Michaël Boyer-Guittaut, Paul Peixoto & Eric Hervouet. (2018) Epigenetic Regulation of EMT (Epithelial to Mesenchymal Transition) and Tumor Aggressiveness: A View on Paradoxical Roles of KDM6B and EZH2. Epigenomes 3:1, pages 1.
Crossref
Federico Pio Fabrizio, Domenico Trombetta, Antonio Rossi, Angelo Sparaneo, Stefano Castellana & Lucia Anna Muscarella. (2018) Gene code CD274/PD-L1 : from molecular basis toward cancer immunotherapy . Therapeutic Advances in Medical Oncology 10, pages 175883591881559.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.